- Clinical-stage biotechnology company BriaCell Therapeutics (NASDAQ:BCTX) priced a public offering of 762,500 common shares at a public offering price of $4.00 per share.
- Total gross proceeds are expected to be $3.05M.
- The offering is expected to close on February 5, 2025.
BriaCell Therapeutics slumps 20%, prices $3M stock offering (NASDAQ:BCTX)
